These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 7925608

  • 21. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
    Bellamy TC, Garthwaite J.
    Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.
    Velardez MO, De Laurentiis A, del Carmen Díaz M, Lasaga M, Pisera D, Seilicovich A, Duvilanski BH.
    Eur J Endocrinol; 2000 Aug; 143(2):279-84. PubMed ID: 10913949
    [Abstract] [Full Text] [Related]

  • 28. Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell.
    Groppi VE, Steinberg F, Kaslow HR, Walker N, Bourne HR.
    J Biol Chem; 1983 Aug 25; 258(16):9717-23. PubMed ID: 6309783
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
    Whalin ME, Scammell JG, Strada SJ, Thompson WJ.
    Mol Pharmacol; 1991 Jun 25; 39(6):711-7. PubMed ID: 1646946
    [Abstract] [Full Text] [Related]

  • 31. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
    Mikashima H, Nakao T, Goto K, Ochi H, Yasuda H, Tsumagari T.
    Thromb Res; 1984 Sep 01; 35(5):589-94. PubMed ID: 6091293
    [Abstract] [Full Text] [Related]

  • 32. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S, Shimooka S, Shimomura H.
    Arch Oral Biol; 2002 Aug 01; 47(8):567-76. PubMed ID: 12221013
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH, Tzeng CC, Teng CM.
    Eur J Pharmacol; 1998 May 15; 349(1):107-14. PubMed ID: 9669503
    [Abstract] [Full Text] [Related]

  • 35. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
    Elks ML, Manganiello VC.
    Endocrinology; 1984 Oct 15; 115(4):1262-8. PubMed ID: 6207009
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L, Luo L, Ju R, Chen C, Zhu L, Li J, Yu X, Ye C, Zhang D.
    Eur J Pharmacol; 2015 Jan 05; 746():14-21. PubMed ID: 25446933
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.